Open AccessACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Author(s) -
Motoo Nagane,
Keiichi Kobayashi,
Kuniaki Saito,
Saki Shimizu,
Shinya Suematsu,
Satoshi Kume,
Yuma Okamura,
Yoshiaki Shiokawa
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy148.080
Subject(s) - temozolomide , medicine , adjuvant , regimen , discontinuation , log rank test , concomitant , oncology , progression free survival , debulking , surgery , overall survival , chemotherapy , cancer , ovarian cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom